Medical Devices

Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

Retrieved on: 
Wednesday, May 1, 2024
Health, Medical Devices, Consumer, Women, Surgery, Health Technology, General Health, Xavier University, FDA, University, ESTA, American Cyanamid, Woman, Regenerative medicine, Breast augmentation, Johnson & Johnson, U.S. FDA, Science, Marketing, MBA, PMA, Organization

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.
  • “Jeff is the ideal person to introduce Motiva to the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • Mr. Ehrhardt was most recently General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics.
  • "Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” said Jeff Ehrhardt.

Eversense® CGM System Receives iCGM Designation by the US FDA

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Health, FDA, Diabetes, Medical Devices, Consumer Electronics, Health Technology, Technology, Consensus, American Diabetes Association, Safety, Physician, De novo, CGM, Partnership, Doctor of Philosophy, Patient, Practitioner, AID, Medical device

iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.

Key Points: 
  • iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
  • “The rigorous data requirements for this FDA designation highlight our team's advanced engineering expertise in developing a CGM that meets high standards.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

Retrieved on: 
Tuesday, April 30, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Atrial fibrillation, Bank, Conference, LAA, Interest

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference.
  • AtriCure’s management is scheduled to present on Tuesday, May 14, 2024, at 10:15 a.m. Pacific Daylight Time.
  • Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com .

Dexios Sees Success in Capturing Charges on the Front-end That Would Cause Denials on the Backend

Retrieved on: 
Tuesday, April 30, 2024
Mobile, Wireless, Technology, Medical Devices, Hospitals, Other Technology, Radiology, General Health, Health, Data Management, Artificial Intelligence, Hospital, AI, Insurance, Partnership, Collection, ICD-10, RCM, Patient, CPT, Medicine, Medicare, MIPS, Maverick, Medical device

Through this collaboration, Maverick and Dexios were able to reduce coding related denials and significantly reduce medical coding queue backlogs by 71 percent.

Key Points: 
  • Through this collaboration, Maverick and Dexios were able to reduce coding related denials and significantly reduce medical coding queue backlogs by 71 percent.
  • This fostered a partnership with Maverick Medical AI in late 2023 when Dexios deployed Maverick’s platform to optimize the billing process by automating the rigorous medical coding process.
  • Reduction of 58 percent in FTE (full-time equivalent): Enables Dexios more staff flexibility, productivity, and better allocation of company resources.
  • Maverick’s Autonomous Medical Coding Platform combines extensive domain knowledge of medical coding with cutting-edge machine learning and generative AI.

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Retrieved on: 
Tuesday, April 30, 2024
Cardiology, Biotechnology, Surgery, Health, FDA, Mental Health, Medical Devices, Clinical Trials, University, Boğaziçi University, Allergan, Inc., LivaNova, Innovation, Research, LIVN, Patient, Chemical engineering, PLC, Bariatric surgery, Tezel

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024.
  • “I am very pleased to welcome Ahmet to the LivaNova team.
  • At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advancing this vision.
  • As Chief Innovation Officer, Ahmet will advance LivaNova’s ability to create novel solutions and elevate the quality of care in neurological and cardiac health for patients around the world,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.

Allurion Announces Preliminary First Quarter 2024 Results

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Managed Care, General Health, Health, Medical Devices, Health Technology, Fitness & Nutrition, Other Health, Obesity, United, Growth, Mobile phone

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.

Key Points: 
  • Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.
  • Management expects preliminary unaudited results for the period as follows:
    Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023
    Procedural volume growth, as estimated by new app users, reflecting 22% growth over the fourth quarter of 2023
    Cash burn in the range of $8 million to $9 million, down from $22 million in the fourth quarter of 2023, and in line with targeted cash burn of approximately $30 million for the year
    “We are encouraged by our growth in the first quarter in both revenue and procedural volume, while slowing our cash burn rate,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer.
  • “We believe awareness and demand for the Allurion Program will continue to grow in subsequent quarters, and we expect the business to feed off of recent catalysts, including the launch of the Allurion Virtual Care Suite in the United States and the first reimbursed procedures in the United Kingdom.”
    The Company will host a conference call on Tuesday, May 14, 2024, at 8:30 AM ET to discuss first quarter financial results and provide a business update.

Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer

Retrieved on: 
Tuesday, April 30, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Lead, Single-cell analysis, Bio-Rad Laboratories, Microfluidics, Marketing, NanoString Technologies, Molecular biology, Genetics, Retirement, IPO, Sphere, Senior, Bachelor of Science, Sphere Fluidics, Acquisition, Synthetic biology, Illumina, Inc., La Trobe University

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.

Key Points: 
  • In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.
  • Throughout his career, Dale has focused on supporting early-stage and VC-backed pioneering tools companies and steering them towards global market success.
  • Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, before becoming CEO in 2010.
  • Dale Levitzke, incoming CEO, Sphere Fluidics, added: “Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development.

Boston Micro Fabrication Launches BMF Biotechnology Inc. to Advance Use of 3D BioChips in Pharmaceutical and Cosmetic Research

Retrieved on: 
Tuesday, April 30, 2024
Research, General Health, Hardware, Pharmaceutical, Technology, Medical Devices, Health Technology, Science, Engineering, Nanotechnology, Biotechnology, Health, Manufacturing, Partner, MPS, Lung cancer, Biochip, Disease, BMF, Liver, Endometrial cancer, Electronics, Multimedia, Drug discovery, Human body, Pharmaceutical industry

To better support the use of highly precise, microfluidic solutions in advanced drug development, pharmaceutical and cosmetic research, Boston Micro Fabrication (BMF) proudly introduces BMF Biotechnology Inc. Headquartered in San Diego, California, BMF Biotechnology Inc. is dedicated to developing and commercializing innovative BioChips (organ-on-a-chip platforms) through cultivating large-scale tissues in vitro, helping accelerate new drug and cosmetic development.

Key Points: 
  • To better support the use of highly precise, microfluidic solutions in advanced drug development, pharmaceutical and cosmetic research, Boston Micro Fabrication (BMF) proudly introduces BMF Biotechnology Inc. Headquartered in San Diego, California, BMF Biotechnology Inc. is dedicated to developing and commercializing innovative BioChips (organ-on-a-chip platforms) through cultivating large-scale tissues in vitro, helping accelerate new drug and cosmetic development.
  • Starting in late 2022, BMF began to expand the business beyond supplying the Projection Micro Stereolithography (PµSL) platform and associated parts delivery.
  • As part of this initiative, BMF inaugurated the San Diego Research Institute, dedicated to advancing innovative microfluidic BioChips for drug discovery and cosmetic testing.
  • To help fully realize the power of the BioChips, BMF Biotechnology is now recruiting collaboration Partners.

ValGenesis Announces Adryan as New Service Partner for Europe

Retrieved on: 
Tuesday, April 30, 2024
Technology, Medical Devices, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, FDA, Partner, Safety, Partnership, ISO, Drug development, GMP, ISPE, Cryptocurrency

Adryan is an internationally operating services group, active throughout western Europe and involved in various associations, such as the ISPE, to develop a sustainable future for life sciences.

Key Points: 
  • Adryan is an internationally operating services group, active throughout western Europe and involved in various associations, such as the ISPE, to develop a sustainable future for life sciences.
  • ValGenesis and Adryan have strengthened their capabilities to assist life sciences companies meet stringent ISO, FDA, and EU regulatory requirements for quality and safety in drug development and manufacturing.
  • “Adryan is a technology innovator contributing to the development of various markets in the life sciences industry in Europe.
  • We are thrilled to partner with market leader ValGenesis, enabling us to provide our network with the best digital validation solutions."

Legacy MEDSearch Named to the Forbes America’s Best Executive Recruiting and Professional Search Firms 2024 List

Retrieved on: 
Tuesday, April 30, 2024
Professional Services, Medical Devices, Health, Health Technology, Other Health, Human Resources, Medtech, Travel, Original equipment manufacturer, Creative industries

Legacy MEDSearch, founded in 2005, today announced that it was named in two categories of the Forbes list of America’s Best Recruiting and Professional Search Firms 2024, presented by Forbes and Statista, Inc.

Key Points: 
  • Legacy MEDSearch, founded in 2005, today announced that it was named in two categories of the Forbes list of America’s Best Recruiting and Professional Search Firms 2024, presented by Forbes and Statista, Inc.
  • The list cited Legacy MEDSearch, a globally recognized medtech and medical device talent advisory firm that sources top talent for industry leaders, for its excellence in the Executive Recruiting and Professional Recruiting categories.
  • The ranking is based on an independent survey of more than 36,800 external recruiters and 16,000 hiring managers, and candidates.
  • “For the sixth year in a row, Forbes has recognized Legacy MEDSearch for our ability to source every critical leadership role, with our deep expertise in medical devices and a network of more than 500,000 professional profiles,” said Legacy MEDSearch founder and CEO Paula Rutledge.